Format

Send to

Choose Destination
Taiwan J Ophthalmol. 2019 Dec 13;9(4):280-283. doi: 10.4103/tjo.tjo_87_17. eCollection 2019 Oct-Dec.

Persistent vitreous hemorrhage after intravitreal injection of dexamethasone intravitreal implant in patients with diabetic macular edema.

Author information

1
Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
2
School of Medicine, National Yang-Ming University, Taipei, Taiwan.

Abstract

We report three cases of persistent vitreous hemorrhage after injection of a biodegradable 0.7 mg dexamethasone intravitreal implant (Ozurdex, Allergan), (DEX) to treat and manage diabetic macular edema (DME); we also summarize available case reports and review the literature regarding persistent vitreous hemorrhage. All three patients underwent pars plana vitrectomy due to nonclearing vitreous hemorrhage after conservative treatment for 2-3 months. During operation, we noted the presence of neovascular membrane along the vascular arcade with taut posterior hyaloid; however, no posterior vitreous detachment (PVD) was found in any of three patients. The implants were carefully preserved, so were the effects in reducing macular edema. Persistent vitreous hemorrhage after DEX injection was rare but manageable without interrupting the effect on DME. Eyes with neovascular membrane but without PVD may be at risk of developing vitreous hemorrhage after DEX injection.

KEYWORDS:

Diabetic macular edema; Ozurdex; vitrectomy; vitreous hemorrhage

Conflict of interest statement

The authors declare that there are no conflicts of interests of this paper.

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center